A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting

مواد مشابهة

• EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
  بواسطة: Nan, Xueli, وآخرون
  منشور في: (2017)
• First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
  بواسطة: Park, Keunchil, وآخرون
  منشور في: (2019)
• First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
  بواسطة: Jeong, Byeong-Ho, وآخرون
  منشور في: (2018)
• EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome
  بواسطة: Tiefenbacher, Andreas, وآخرون
  منشور في: (2017)
• The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
  بواسطة: Okamoto, Isamu, وآخرون
  منشور في: (2010)